{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:23:06Z","timestamp":1790677386876,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1016\/j.nmd.2007.03.006","type":"journal-article","created":{"date-parts":[[2007,5,2]],"date-time":"2007-05-02T10:37:24Z","timestamp":1178102244000},"page":"537-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Impact of late-onset Pompe disease on participation in daily life activities: Evaluation of the Rotterdam Handicap Scale"],"prefix":"10.1016","volume":"17","author":[{"given":"M.L.C.","family":"Hagemans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.C.","family":"Hop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.S.J.","family":"Merkies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.J.","family":"Reuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.","family":"Van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2007.03.006_bib1","series-title":"The metabolic and molecular bases of inherited disease","first-page":"3389","article-title":"Glycogen storage disease type II; acid alpha-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.nmd.2007.03.006_bib2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.nmd.2007.03.006_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.nmd.2007.03.006_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2007.03.006_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2007.03.006_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2004.10.009","article-title":"Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial","volume":"15","author":"Klinge","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2007.03.006_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2007.03.006_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ana.20019","article-title":"Enzyme replacement therapy in late-onset Pompe\u2019s disease: a three-year follow-up","volume":"55","author":"Winkel","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2007.03.006_bib9","unstructured":"World Health Organisation. International classification of functioning, disability and health. Geneva: WHO; 2001."},{"key":"10.1016\/j.nmd.2007.03.006_bib10","series-title":"Gross motor function measure manual","author":"Russel","year":"1993"},{"key":"10.1016\/j.nmd.2007.03.006_bib11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1469-8749.2003.tb00966.x","article-title":"Pompe disease and physical disability","volume":"45","author":"Haley","year":"2003","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2007.03.006_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1363849031000139298","article-title":"Development of a disease-specific disability instrument for Pompe disease","volume":"6","author":"Haley","year":"2003","journal-title":"Pediatr Rehabil"},{"key":"10.1016\/j.nmd.2007.03.006_bib13","unstructured":"World Health Organisation. International classification of impairments, disabilities, and handicaps. Geneva: WHO; 1980."},{"key":"10.1016\/j.nmd.2007.03.006_bib14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/01.wnl.0000198776.53007.2c","article-title":"Course of disability and respiratory function in untreated late-onset Pompe disease","volume":"66","author":"Hagemans","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2007.03.006_bib15","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","article-title":"Disease severity in children and adults with Pompe disease related to age and disease duration","volume":"64","author":"Hagemans","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2007.03.006_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2007.03.006_bib17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.10045","article-title":"Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies","volume":"25","author":"Merkies","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2007.03.006_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/0963828031000137081","article-title":"Measuring participation according to the International Classification of Functioning, Disability and Health (ICF)","volume":"25","author":"Perenboom","year":"2003","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.nmd.2007.03.006_bib19","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1212\/01.WNL.0000142597.69707.78","article-title":"Late-onset Pompe disease primarily affects quality of life in physical health domains","volume":"63","author":"Hagemans","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2007.03.006_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.nmd.2007.03.006_bib21","series-title":"SF-36 health survey: manual and interpretation guide","author":"Ware","year":"1993"},{"key":"10.1016\/j.nmd.2007.03.006_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-4356(98)00083-3","article-title":"Cross-cultural comparisons of the content of SF-36 translations across 10 countries: results from the IQOLA Project. International Quality of Life Assessment","volume":"51","author":"Wagner","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.nmd.2007.03.006_bib23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0895-4356(98)00086-9","article-title":"Methods for validating and norming translations of health status questionnaires: the IQOLA project approach. International Quality of Life Assessment","volume":"51","author":"Gandek","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"Suppl. 1","key":"10.1016\/j.nmd.2007.03.006_bib24","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1007\/BF02680006","article-title":"Enzyme therapy for Pompe disease: from science to industrial enterprise","volume":"161","author":"Reuser","year":"2002","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.nmd.2007.03.006_bib25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2007.03.006_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jnnp.74.1.99","article-title":"Connecting impairment, disability, and handicap in immune mediated polyneuropathies","volume":"74","author":"Merkies","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2007.03.006_bib27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00415-005-0958-x","article-title":"Long term disability and social status change after Guillain\u2013Barre syndrome","volume":"253","author":"Bersano","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2007.03.006_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/jnnp.2004.046227","article-title":"Amantadine for treatment of fatigue in Guillain\u2013Barre syndrome: a randomised, double blind, placebo controlled, crossover trial","volume":"77","author":"Garssen","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nmd.2007.03.006_bib29","series-title":"Psychometric theory","author":"Nunnally","year":"1994"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896607000879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896607000879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:55:27Z","timestamp":1760774127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896607000879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["S0960896607000879"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2007.03.006","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2007,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of late-onset Pompe disease on participation in daily life activities: Evaluation of the Rotterdam Handicap Scale","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2007.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}